F
Forte Biosciences, Inc. (FBRX)
NCM – Real Time Price. Currency in USD
21.03
+2.32 (12.40%)
At close: Jun 26, 2026, 4:00 PM EDT
21.03
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:43 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
21.03
+2.32 (12.40%)
At close: Jun 26, 2026, 4:00 PM EDT
21.03
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:43 PM EDT
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
| Name | Position |
|---|---|
| Dr. Barbara K. Finck M.D. | Acting Senior Medical Clinician & Director |
| Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman |
| Mr. Antony A. Riley CPA | Chief Financial Officer |
| Mr. Christopher Roenfeldt | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-08 | S-3/A | d117004ds3a.htm |
| 2026-06-02 | S-3 | d117004ds3.htm |
| 2026-06-02 | 8-K | d110060d8k.htm |
| 2026-05-14 | 8-K | d95486d8k.htm |
| 2026-05-11 | 10-Q | fbrx-20260331.htm |
| 2026-04-29 | DEF 14A | d936120ddef14a.htm |
| 2026-04-29 | ARS | d66937dars.pdf |
| 2026-04-09 | 8-K | d128424d8k.htm |
| 2026-04-01 | 8-K | d63145d8k.htm |
| 2026-03-31 | 10-K | fbrx-20251231.htm |